Weekly Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings

May 17, 2018 - By Elizabeth Jones

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.23. That’s change of 0.45, from 2017Q3’s 0.78. 24 investors sold all, 67 reduced holdings as Seattle Genetics, Inc. ratio improved. 68 rose stakes while 44 funds bought stakes. Funds hold 141.83 million shares thus 1.14% more from 2017Q3’s 140.23 million shares.
Grandfield & Dodd Limited Company reported 0.06% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN). The Pennsylvania-based Jfs Wealth Advsr Ltd Company has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Schwab Charles Inv Mngmt owns 323,051 shs or 0.01% of their US capital. Eventide Asset Management Ltd Liability Corp accumulated 525,000 shs. 4,860 are owned by Manufacturers Life Com The. 5,250 were reported by Badgley Phelps And Bell. Pinnacle Assocs Limited holds 0.96% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 930,673 shs. Landscape Mgmt Lc invested in 0.08% or 16,964 shs. Eqis Cap stated it has 0.07% in Seattle Genetics, Inc. (NASDAQ:SGEN). Mitsubishi Ufj And Bk stated it has 0.09% in Seattle Genetics, Inc. (NASDAQ:SGEN). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Barclays Pcl holds 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 17,316 shs. Baker Bros Advsrs L P holds 21.2% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 45.73 million shs. Pnc Financial Serv Gp stated it has 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Sei Invs accumulated 13,379 shs.

Seattle Genetics, Inc. had 10 selling transactions and 3 insider buys since December 11, 2017. This’s net activity of $268.25 million. Cline Darren S had sold 9,000 shs worth $497,983. On Friday, May 4 BAKER BROS. ADVISORS LP bought $24.57 million worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 460,651 shs. DRACHMAN JONATHAN G sold $552,452 worth of stock. $290,604 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shs were sold by HIMES VAUGHN B.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Total analysts of 8 have positions in Seattle Genetics (NASDAQ:SGEN) as follows: 6 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 75%. Since January 31, 2018 according to StockzIntelligence Inc Seattle Genetics has 11 analyst reports. On Wednesday, February 7 the rating was maintained by SunTrust with “Hold”. On Wednesday, March 21 the company was maintained by Morgan Stanley. In Wednesday, February 14 report J.P. Morgan upgraded the stock to “Buy” rating. On Wednesday, January 31 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given by RBC Capital Markets. The company rating was maintained by H.C. Wainwright on Friday, April 27. On Tuesday, March 20 RBC Capital Markets maintained the shares of SGEN in report with “Buy” rating. On Thursday, February 1 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given by H.C. Wainwright. In Wednesday, February 7 report Bank of America maintained it with “Neutral” rating and $68 target. In Wednesday, February 7 report Needham maintained the stock with “Buy” rating. In Wednesday, February 7 report H.C. Wainwright maintained the stock with “Buy” rating. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain

SGEN hit $57.33 during the last trading session after $1.17 change.Seattle Genetics, Inc. has volume of 910,426 shares. Since May 17, 2017 SGEN has declined 20.48% and is downtrending. SGEN underperformed by 32.03% the S&P 500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is worth $9.07 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Currently it has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

For more Seattle Genetics, Inc. (NASDAQ:SGEN) news brought out recently go to: Streetinsider.com, Businesswire.com, Nasdaq.com, Businesswire.com or Seekingalpha.com. The titles are as follows: “Seattle Genetics (SGEN) Announces Data Presentations at ASCO” brought out on May 17, 2018, “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” on May 17, 2018, “Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags …” with a publish date: May 09, 2018, “Seattle Genetics Appoints Roger D. Dansey, MD, Chief Medical Officer” and the last “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” with publication date: April 27, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.